Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1

Azole antifungal agents: emphasis on new triazoles.

M S Saag 1, W E Dismukes 1
PMCID: PMC172087  PMID: 2831809

Abstract

Many advances have been made in antifungal therapy over the last three decades. Itraconazole and fluconazole, two investigational triazole agents, are the most recent additions to the list of antifungal drugs. This review has focused primarily on their mechanisms of action, favorable pharmacologic properties, and spectra of activity against a broad range of systemic pathogens. Itraconazole and fluconazole show much promise as orally active agents, with less potential for toxicity than the currently available azoles. Fluconazole and, to a lesser degree, itraconazole are especially promising therapies for cryptococcal meningitis. In addition, fluconazole may prove to be highly effective in urinary tract infections caused by Candida species and other fungi. Ongoing and future clinical trials will more clearly define the specific roles of itraconazole and fluconazole in the treatment of systemic mycoses.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S57–S63. doi: 10.1093/clinids/9.supplement_1.s57. [DOI] [PubMed] [Google Scholar]
  2. Brass C., Galgiani J. N., Blaschke T. F., Defelice R., O'Reilly R. A., Stevens D. A. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982 Jan;21(1):151–158. doi: 10.1128/aac.21.1.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Daneshmend T. K., Warnock D. W., Ene M. D., Johnson E. M., Potten M. R., Richardson M. D., Williamson P. J. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother. 1984 Jan;25(1):1–3. doi: 10.1128/aac.25.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. De Nollin S., Van Belle H., Goossens F., Thone F., Borgers M. Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob Agents Chemother. 1977 Mar;11(3):500–513. doi: 10.1128/aac.11.3.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DeFelice R., Johnson D. G., Galgiani J. N. Gynecomastia with ketoconazole. Antimicrob Agents Chemother. 1981 Jun;19(6):1073–1074. doi: 10.1128/aac.19.6.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Drouhet E., Dupont B. Evolution of antifungal agents: past, present, and future. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S4–14. doi: 10.1093/clinids/9.supplement_1.s4. [DOI] [PubMed] [Google Scholar]
  7. Drouhet E., Dupont B. Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am J Med. 1983 Jan 24;74(1B):30–47. doi: 10.1016/0002-9343(83)90512-0. [DOI] [PubMed] [Google Scholar]
  8. Dupont B., Drouhet E. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S71–S76. doi: 10.1093/clinids/9.supplement_1.s71. [DOI] [PubMed] [Google Scholar]
  9. Engelhard D., Stutman H. R., Marks M. I. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med. 1984 Dec 27;311(26):1681–1683. doi: 10.1056/NEJM198412273112606. [DOI] [PubMed] [Google Scholar]
  10. Espinel-Ingroff A., Shadomy S., Gebhart R. J. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5–9. doi: 10.1128/aac.26.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ganer A., Arathoon E., Stevens D. A. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S77–S86. doi: 10.1093/clinids/9.supplement_1.s77. [DOI] [PubMed] [Google Scholar]
  12. Graybill J. R., Ahrens J. Itraconazole treatment of murine aspergillosis. Sabouraudia. 1985 Jun;23(3):219–223. doi: 10.1080/00362178585380321. [DOI] [PubMed] [Google Scholar]
  13. Graybill J. R., Ahrens J. R 51211 (itraconazole) therapy of murine cryptococcosis. Sabouraudia. 1984;22(6):445–453. doi: 10.1080/00362178485380721. [DOI] [PubMed] [Google Scholar]
  14. Graybill J. R., Palou E., Ahrens J. Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am Rev Respir Dis. 1986 Oct;134(4):768–770. doi: 10.1164/arrd.1986.134.4.768. [DOI] [PubMed] [Google Scholar]
  15. Heel R. C., Brogden R. N., Carmine A., Morley P. A., Speight T. M., Avery G. S. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs. 1982 Jan-Feb;23(1-2):1–36. doi: 10.2165/00003495-198223010-00001. [DOI] [PubMed] [Google Scholar]
  16. Horsburgh C. R., Jr, Kirkpatrick C. H. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med. 1983 Jan 24;74(1B):23–29. doi: 10.1016/0002-9343(83)90511-9. [DOI] [PubMed] [Google Scholar]
  17. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Janssen P. A., Symoens J. E. Hepatic reactions during ketoconazole treatment. Am J Med. 1983 Jan 24;74(1B):80–85. doi: 10.1016/0002-9343(83)90519-3. [DOI] [PubMed] [Google Scholar]
  19. Johnson E. M., Richardson M. D., Warnock D. W. Effect of imidazole antifungals on the development of germ tubes by strains of Candida albicans. J Antimicrob Chemother. 1983 Oct;12(4):303–316. doi: 10.1093/jac/12.4.303. [DOI] [PubMed] [Google Scholar]
  20. Kobayashi G. S., Travis S., Medoff G. Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother. 1986 Apr;29(4):660–662. doi: 10.1128/aac.29.4.660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lewis J. H., Zimmerman H. J., Benson G. D., Ishak K. G. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984 Mar;86(3):503–513. [PubMed] [Google Scholar]
  22. Lyman C. A., Sugar A. M., Diamond R. D. Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice. Antimicrob Agents Chemother. 1986 Jan;29(1):161–162. doi: 10.1128/aac.29.1.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McEwen J. G., Peters G. R., Blaschke T. F., Brummer E., Perlman A. M., Restrepo A., Stevens D. A. Treatment of paracoccidioidomycosis with itraconazole in a murine model. J Trop Med Hyg. 1985 Oct;88(5):295–299. [PubMed] [Google Scholar]
  24. Negroni R., Palmieri O., Koren F., Tiraboschi I. N., Galimberti R. L. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S47–S50. doi: 10.1093/clinids/9.supplement_1.s47. [DOI] [PubMed] [Google Scholar]
  25. Odds F. C., Webster C. E., Abbott A. B. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother. 1984 Aug;14(2):105–114. doi: 10.1093/jac/14.2.105. [DOI] [PubMed] [Google Scholar]
  26. Palou de Fernandez E., Patino M. M., Graybill J. R., Tarbit M. H. Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother. 1986 Aug;18(2):261–270. doi: 10.1093/jac/18.2.261. [DOI] [PubMed] [Google Scholar]
  27. Perfect J. R., Durack D. T. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81–86. doi: 10.1093/jac/16.1.81. [DOI] [PubMed] [Google Scholar]
  28. Perfect J. R., Savani D. V., Durack D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. doi: 10.1128/aac.29.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Petersen E. A., Alling D. W., Kirkpatrick C. H. Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial. Ann Intern Med. 1980 Dec;93(6):791–795. doi: 10.7326/0003-4819-93-6-791. [DOI] [PubMed] [Google Scholar]
  30. Plempel M., Büchel K. H., Bartmann K., Regel E. Antimycotic properties of clotrimazole. Postgrad Med J. 1974 Jul;50 (Suppl 1):11–12. [PubMed] [Google Scholar]
  31. Pont A., Graybill J. R., Craven P. C., Galgiani J. N., Dismukes W. E., Reitz R. E., Stevens D. A. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984 Nov;144(11):2150–2153. [PubMed] [Google Scholar]
  32. Pont A., Williams P. L., Azhar S., Reitz R. E., Bochra C., Smith E. R., Stevens D. A. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982 Nov;142(12):2137–2140. [PubMed] [Google Scholar]
  33. Pont A., Williams P. L., Loose D. S., Feldman D., Reitz R. E., Bochra C., Stevens D. A. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982 Sep;97(3):370–372. doi: 10.7326/0003-4819-97-3-370. [DOI] [PubMed] [Google Scholar]
  34. Restrepo A., Gomez I., Robledo J., Patiño M. M., Cano L. E. Itraconazole in the treatment of paracoccidioidomycosis: a preliminary report. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S51–S56. doi: 10.1093/clinids/9.supplement_1.s51. [DOI] [PubMed] [Google Scholar]
  35. Restrepo A., Gómez I., Cano L. E., Arango M. D., Gutiérrez F., Sanín A., Robledo M. A. Post-therapy status of paracoccidioidomycosis treated with ketoconazole. Am J Med. 1983 Jan 24;74(1B):53–57. doi: 10.1016/0002-9343(83)90514-4. [DOI] [PubMed] [Google Scholar]
  36. Restrepo A., Gómez I., Cano L. E., Arango M. D., Gutiérrez F., Sanín A., Robledo M. A. Treatment of paracoccidioidomycosis with ketoconazole: a three-year experience. Am J Med. 1983 Jan 24;74(1B):48–52. doi: 10.1016/0002-9343(83)90513-2. [DOI] [PubMed] [Google Scholar]
  37. Richardson K., Brammer K. W., Marriott M. S., Troke P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rogers T. E., Galgiani J. N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986 Sep;30(3):418–422. doi: 10.1128/aac.30.3.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Shadomy S., White S. C., Yu H. P., Dismukes W. E. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis. 1985 Dec;152(6):1249–1256. doi: 10.1093/infdis/152.6.1249. [DOI] [PubMed] [Google Scholar]
  40. Shigematsu M. L., Uno J., Arai T. Effect of ketoconazole on isolated mitochondria from Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):919–924. doi: 10.1128/aac.21.6.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Stevens D. A., Stiller R. L., Williams P. L., Sugar A. M. Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis. Am J Med. 1983 Jan 24;74(1B):58–63. doi: 10.1016/0002-9343(83)90515-6. [DOI] [PubMed] [Google Scholar]
  42. Sud I. J., Chou D. L., Feingold D. S. Effect of free fatty acids on liposome susceptibility to imidazole antifungals. Antimicrob Agents Chemother. 1979 Nov;16(5):660–663. doi: 10.1128/aac.16.5.660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Ann Intern Med. 1985 Dec;103(6 ):861–872. [PubMed] [Google Scholar]
  44. Troke P. F., Andrews R. J., Brammer K. W., Marriott M. S., Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother. 1985 Dec;28(6):815–818. doi: 10.1128/aac.28.6.815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Troke P. F., Andrews R. J., Marriott M. S., Richardson K. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother. 1987 May;19(5):663–670. doi: 10.1093/jac/19.5.663. [DOI] [PubMed] [Google Scholar]
  46. Tucker W. S., Jr, Snell B. B., Island D. P., Gregg C. R. Reversible adrenal insufficiency induced by ketoconazole. JAMA. 1985 Apr 26;253(16):2413–2414. [PubMed] [Google Scholar]
  47. Uno J., Shigematsu M. L., Arai T. Primary site of action of ketoconazole on Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):912–918. doi: 10.1128/aac.21.6.912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Van Cauteren H., Heykants J., De Coster R., Cauwenbergh G. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S43–S46. doi: 10.1093/clinids/9.supplement_1.s43. [DOI] [PubMed] [Google Scholar]
  49. Van Cutsem J., Van Gerven F., Janssen P. A. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S15–S32. doi: 10.1093/clinids/9.supplement_1.s15. [DOI] [PubMed] [Google Scholar]
  50. Van Cutsem J., Van Gerven F., Van de Ven M. A., Borgers M., Janssen P. A. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother. 1984 Oct;26(4):527–534. doi: 10.1128/aac.26.4.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Van den Bossche H., Willemsens G., Cools W., Cornelissen F., Lauwers W. F., van Cutsem J. M. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother. 1980 Jun;17(6):922–928. doi: 10.1128/aac.17.6.922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Van den Bossche H., Willemsens G., Cools W., Marichal P., Lauwers W. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem Soc Trans. 1983 Dec;11(6):665–667. doi: 10.1042/bst0110665. [DOI] [PubMed] [Google Scholar]
  53. Vanden Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Curr Top Med Mycol. 1985;1:313–351. doi: 10.1007/978-1-4613-9547-8_12. [DOI] [PubMed] [Google Scholar]
  54. de Brabander M., Aerts F., van Cutsem J., van den Bossche H., Borgers M. The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans. Sabouraudia. 1980 Sep;18(3):197–210. doi: 10.1080/00362178085380351. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES